Literature DB >> 27186315

Icariin exerts estrogen-like activity in ameliorating EAE via mediating estrogen receptor β, modulating HPA function and glucocorticoid receptor expression.

Zhisheng Wei1, Mengxia Wang2, Mingfan Hong1, Shengpeng Diao1, Aiqun Liu1, Yeqing Huang1, Qingyun Yu1, Zhongxing Peng1.   

Abstract

BACKGROUND: Estrogen exerts neuroprotective and anti-inflammatory effects in EAE and multiple sclerosis (MS), but its clinical application is hindered due to side effects and risk of tumor. Phytoestrogen structurally or functionally mimics estrogen with fewer side effects than endogenous estrogen. Icariin (ICA), an active component of Epimedium extracts, demonstrates estrogen-like neuroprotective effects. However, it is unclear whether ICA is effective in EAE and what are the underlying mechanisms.
OBJECTIVE: To determine the therapeutic effects of ICA in EAE and explore the possible mechanisms.
METHODS: C57BL/6 EAE mice were treated with Diethylstilbestrol, different dose of ICA and mid-dose ICA combined with ICI 182780. The clinical scores and serum Interleukin-17 (IL-17), Corticosterone (CORT) concentrations were then analyzed. Western blot were performed to investigate the expressions of glucocorticoid receptor (GR), estrogen receptor alpha (ERα) and ERβ in the cerebral white matter of EAE mice.
RESULTS: High dose ICA is equally effective in ameliorating neurological signs of EAE as estrogen. Estrogen and ICA has no effects on serum concentrations of IL-17 in EAE. While the CORT levels were decreased by ICA at mid or high doses, the expressions of GR, ERα and ERβ were up-regulated by estrogen or different doses of ICA in a dosedependent manner. Estrogen induced the elevation of ERα more markedly than ICA. In contrast, ICA at mid and high doses promoted ERβ more significantly than estrogen.
CONCLUSION: ICA exerts estrogen-like activity in ameliorating EAE via mediating ERβ, modulating HPA function and up-regulating the expression of GR in cerebral white matter. ICA may be a promising therapeutic option for MS.

Entities:  

Keywords:  Icariin; estrogen; estrogen receptor; experimental autoimmune encephalomyelitis; glucocorticoid receptor; hypothalamic-pituitary-adrenal; multiple sclerosis

Year:  2016        PMID: 27186315      PMCID: PMC4859920     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  39 in total

1.  Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse.

Authors:  J F Couse; J Lindzey; K Grandien; J A Gustafsson; K S Korach
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

2.  Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis.

Authors:  Laurie Beth J Morales; Kyi Kyi Loo; Hong-Biao Liu; Cory Peterson; Seema Tiwari-Woodruff; Rhonda R Voskuhl
Journal:  J Neurosci       Date:  2006-06-21       Impact factor: 6.167

3.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

4.  Icariin attenuates social defeat-induced down-regulation of glucocorticoid receptor in mice.

Authors:  Jinfeng Wu; Juan Du; Changqing Xu; Jingjing Le; Yizhe Xu; Baojun Liu; Jingcheng Dong
Journal:  Pharmacol Biochem Behav       Date:  2011-01-20       Impact factor: 3.533

5.  Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats.

Authors:  Min-You Qi; Hao-Ran Liu; Yan-hui Su; Su-Qing Yu
Journal:  J Ethnopharmacol       Date:  2011-10-19       Impact factor: 4.360

6.  Icariin attenuates glucocorticoid insensitivity mediated by repeated psychosocial stress on an ovalbumin-induced murine model of asthma.

Authors:  Bei Li; Xiaohong Duan; Changqing Xu; Jinfeng Wu; Baojun Liu; Yiji Du; Qingli Luo; Hualiang Jin; Weiyi Gong; Jingcheng Dong
Journal:  Int Immunopharmacol       Date:  2014-01-22       Impact factor: 4.932

Review 7.  Estrogen receptor alpha and beta in health and disease.

Authors:  Min Jia; Karin Dahlman-Wright; Jan-Åke Gustafsson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-04-26       Impact factor: 4.690

8.  HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter.

Authors:  Jeroen Melief; Stella J de Wit; Corbert G van Eden; Charlotte Teunissen; Jörg Hamann; Bernard M Uitdehaag; Dick Swaab; Inge Huitinga
Journal:  Acta Neuropathol       Date:  2013-06-28       Impact factor: 17.088

9.  Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12.

Authors:  Burkhard Becher; Brigit G Durell; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

10.  Oestrogen receptor beta ligand: a novel treatment to enhance endogenous functional remyelination.

Authors:  Daniel K Crawford; Mario Mangiardi; Bingbing Song; Rhusheet Patel; Sienmi Du; Michael V Sofroniew; Rhonda R Voskuhl; Seema K Tiwari-Woodruff
Journal:  Brain       Date:  2010-09-21       Impact factor: 13.501

View more
  13 in total

Review 1.  The "Gut Feeling": Breaking Down the Role of Gut Microbiome in Multiple Sclerosis.

Authors:  Samantha N Freedman; Shailesh K Shahi; Ashutosh K Mangalam
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

Review 2.  Stem Cells and Natural Agents in the Management of Neurodegenerative Diseases: A New Approach.

Authors:  Aranka Brockmueller; Negin Mahmoudi; Amir Kian Movaeni; Anna-Lena Mueller; Abdol-Mohammad Kajbafzadeh; Mehdi Shakibaei; Masoumeh Majidi Zolbin
Journal:  Neurochem Res       Date:  2022-09-16       Impact factor: 4.414

Review 3.  The effect of icariin on immunity and its potential application.

Authors:  Rong Shen; Ju-Hua Wang
Journal:  Am J Clin Exp Immunol       Date:  2018-06-05

Review 4.  Neurovascular glucocorticoid receptors and glucocorticoids: implications in health, neurological disorders and drug therapy.

Authors:  Sherice Williams; Chaitali Ghosh
Journal:  Drug Discov Today       Date:  2019-09-18       Impact factor: 7.851

5.  Synthesis and Biological Evaluation of Novel Alkyl Amine Substituted Icariside II Derivatives as Potential Anticancer Agents.

Authors:  Tong Wu; Ting Li; Ya-Nan Kang; Li Liu; Xi-Man Wang; Jin-Shuai Lan; Yue Ding; Tong Zhang
Journal:  Molecules       Date:  2018-08-27       Impact factor: 4.411

6.  Improved Pharmacokinetics of Icariin (ICA) within Formulation of PEG-PLLA/PDLA-PNIPAM Polymeric Micelles.

Authors:  Lu-Ying Han; Yun-Long Wu; Chun-Yan Zhu; Cai-Sheng Wu; Chun-Rong Yang
Journal:  Pharmaceutics       Date:  2019-01-25       Impact factor: 6.321

7.  A Network Pharmacology Approach to Estimate Potential Targets of the Active Ingredients of Epimedium for Alleviating Mild Cognitive Impairment and Treating Alzheimer's Disease.

Authors:  Xianwei Gao; Shengnan Li; Chao Cong; Yuejiao Wang; Lianwei Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-28       Impact factor: 2.629

8.  Lignans intake and enterolactone concentration and prognosis of breast cancer: a systematic review and meta-analysis.

Authors:  Zhen Liu; Yin-Jiao Fei; Xin-Hui Cao; Di Xu; Wen-Juan Tang; Kai Yang; Wen-Xiu Xu; Jin-Hai Tang
Journal:  J Cancer       Date:  2021-03-10       Impact factor: 4.207

9.  Neuroprotective effects of icariin in neonatal hypoxia-ischemic brain damage via its anti-apoptotic property.

Authors:  Mengxia Wang; Ying Rong; Li Luo
Journal:  Childs Nerv Syst       Date:  2020-07-15       Impact factor: 1.532

Review 10.  Beyond Metabolism: The Complex Interplay Between Dietary Phytoestrogens, Gut Bacteria, and Cells of Nervous and Immune Systems.

Authors:  Nicole Cady; Stephanie R Peterson; Samantha N Freedman; Ashutosh K Mangalam
Journal:  Front Neurol       Date:  2020-03-13       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.